Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?

Irmak Duygu Koyuncu, Darıcı Hakan, Karaöz Erdal

Table 5 The trials with other design characteristics along with their development phases, participant size blinding status and the treatment intervention types to cure SARS-CoV infection in ICTP database of WHO.

Protocol design: Selected Trials with Other Design Characteristics Trial ID Phase / Target Participants Design Intervention NCT04252118 Phase 1 / 20 Subjects parallel open label Experimental Group: 3 times of MSCs (3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6). Control Group: Without MSCs Therapy but conventional treatment should be received. NCT04276987 Phase 1 / 30 Subjects Single arm MSCs-derived exosomes (5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).) NCT04313322 Phase 1 / 5 Subjects Single arm open label WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs. NCT04315987 Phase 1 / 66 Subjects single arm open label NestCell® is a mesenchymal stem cell therapy produced by Cellavita NCT04331613 Phase 1-2 / 9 Subjects single arm open label CAStem will be administered intravenously. Human Embryonic Stem Cells Derived M Cells (CAStem) A dose-escalation with 3 cohorts with 3 patients/cohort who receive doses of 3, 5 or 10 million cells/kg. If there are no safety concerns for each cohort, the dose will be escalated from lower dose to next higher dose. NCT04302519 Phase early 1 / 24 Subjects single arm open label Dental pulp mesenchymal stem cells On the basis of clinical standard treatment, the injection of dental mesenchymal stem cells was increased on day 1, 3 and 7 of the trial.